anti-p63 (human) Rabbit Monoclonal (RM383)

Tumor Protein 63

N/A

32160000

liquid

Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.

Avoid freeze/thaw cycles.

A peptide corresponding to the area surrounding the C-terminus of human p63 (Tumor protein 63).

Recombinant Antibody. This antibody reacts to human p63 (Tumor protein 63). Applications: WB, IHC. Source: Rabbit. Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. p63 (TP63; Tumor protein 63) acts as a sequence-specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform-specific activity. p63 may be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. It is involved in Notch signaling by inducing JAG1 and JAG2. p63 plays a role in the regulation of epithelial morphogenesis. p63 is required for limb formation from the apical ectodermal ridge. It also activates transcription of the p21 promoter. Mutations affecting the gene can result in acro-dermato-ungual-lacrimal-tooth syndrome, ankyloblepharon-ectodermal defects-cleft lip/palate, ectrodactyly ectodermal dysplasia, split-hand/foot malformation 4, limb-mammary syndrome, ectodermal dysplasia and orofacial cleft. p63 immunostaining has utility for head and neck squamous cell carcinomas, differentiating prostatic adenocarcinoma and benign prostatic tissue. p63 is also helpful in distinguishing poorly differentiated squamous cell carcinoma from small cell carcinoma or adenocarcinoma. p63 should be strongly stained in poorly differentiated squamous cell, but negative in small cell or adenocarcinoma.

Q9H3D4?

Vial

p63 (TP63; Tumor protein 63) acts as a sequence-specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform-specific activity. p63 may be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. It is involved in Notch signaling by inducing JAG1 and JAG2. p63 plays a role in the regulation of epithelial morphogenesis. p63 is required for limb formation from the apical ectodermal ridge. It also activates transcription of the p21 promoter. Mutations affecting the gene can result in acro-dermato-ungual-lacrimal-tooth syndrome, ankyloblepharon-ectodermal defects-cleft lip/palate, ectrodactyly ectodermal dysplasia, split-hand/foot malformation 4, limb-mammary syndrome, ectodermal dysplasia and orofacial cleft. p63 immunostaining has utility for head and neck squamous cell carcinomas, differentiating prostatic adenocarcinoma and benign prostatic tissue. p63 is also helpful in distinguishing poorly differentiated squamous cell carcinoma from small cell carcinoma or adenocarcinoma. p63 should be strongly stained in poorly differentiated squamous cell, but negative in small cell or adenocarcinoma.

Protein A purified.

Rabbit

This antibody reacts to human p63 (Tumor protein 63).

Non-hazardous

Primary Antibodies

12352203

Stable for at least 1 year after receipt when stored at -20°C.